SAS in Patients With Bronchial Carcinoma

Not Applicable

• Conditions: Sleep Apnea Syndrome; Bronchial Carcinoma
• Interventions: Device: sleep apnea screening with ApneaLinkTM

• Registration Number: NCT02270853
• Lead Sponsor: RWTH Aachen University

Brief Summary

In this study it will be analyzed how often the sleep apnea syndrome can be observed in patients with newly diagnosed lung cancer with the help of ApneaLink device by ResMed.

Detailed Description

Determination of the SAS- frequence in patients with bronchial carcinoma. The patients will be screened at home for 1 night with the ApneaLink device by ResMed. The apneaLink device is a standard screening tool for sleep apnea in clinical practice.

Study Timeline

• Study Start: 2014-04
• Study First Submitted: 2014-10-14
• Study First Submitted QC: 2014-10-20
• Study First Posted: 2014-10-21
• Status Verified: 2016-02
• Last Update Submitted: 2016-02-17
• Last Update Posted: 2016-02-18
• Primary Completion: 2016-12
• Study Completion: 2016-12

Recruitment & Eligibility

• Status: UNKNOWN
• Sex: All
• Target Recruitment: 100

Inclusion Criteria

• Patients with reasonable suspicion of bronchial carcinoma or histologically proven bronchial carcinoma, which has not been medicated until the study entry and
• Patients with sleep apnea who had recently been diagnosed with bronchial carcinoma.

Exclusion Criteria

• Pregnancy
• other already known malignancies or tumors
• Patients with non-invasive artificial respiration due to a chronic respiratory insufficiencies

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Arm && Interventions

Group	Intervention	Description
sleep apnea screening with ApneaLinkTM	sleep apnea screening with ApneaLinkTM	This is the only group in the present study. Patients with bronchial carcinoma (or reasonable suspicion) perform sleep screening with ApneaLinkTM at home or during the hospitalization.

Primary Outcome Measures

Name	Time	Method
percent of sleep apnea in patients with bronchial carcinoma	two days	The percent of sleep apnea in a cohort of patients with bronchial carcinoma will be evaluated. The duration of the study participation is two days.

Trial Locations

Locations (3)

Medizinische Klinik I Uniklinik RWTH Aachen; 🇩🇪 Aachen, NRW, Germany

Krankenhaus Merheim; 🇩🇪 Köln, NRW, Germany

Florence-Nightingale Hospital; 🇩🇪 Düsseldorf, Germany